Colossal Bioscience’s attempt to de-extinct the dire wolf is a dangerously deceptive publicity stunt
By David Coltman, Carson Mitchell, Liam Alastair Wayde Carter, and Tommy Galfano,
The Conversation
| 05. 12. 2025
Colossal Biosciences, a Texas-based biotech company, made headlines this April after falsely claiming to resurrect the extinct dire wolf. The company presents this as a breakthrough for conservation biology. However, our team of conservation geneticists at the Western University — along with many other academics views it as a dangerous deception.
Colossal’s so-called dire wolf is not a resurrected species. It’s a genetically modified grey wolf. Its creation is a publicity stunt designed to generate profit, with serious consequences.
Jenga approach to conservation
Conservation aims to safeguard ecosystems by preserving the networks of interaction between animals and their environment. Human activity has caused widespread habitat loss, driving extinction rates to levels estimated to be about 1,000 times higher than the natural background rate. We are living through a biodiversity crisis, and conservation remains our only real defence against further declines.
Colossal proposes de-extinction to combat this crisis, using a Jenga-block metaphor to explain their approach. The ecosystem is a Jenga tower, with each species representing a block — and losing a species weakens the structure, pushing it...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...